Should preserving contract pharmacy arrangements be a policy priority when the evidence shows that many of these arrangements ...

A federal district court ruled in favor of the Health Resources and Services Administration, but raised questions about ...

A district court ruled that the HHS does have the power to review drug manufacturers’ plans to pay hospitals rebates instead ...

HRSA generally advised covered entities to ensure that their handling of 340B matters as part of their emergency responses is incorporated into their 340B policies and procedures and that they ...

underscored the impact J&J's policy would have on disproportionate share hospitals and reaffirmed HRSA's interpretation of the 340B statute. Both groups encouraged the administrator not to waste ...

rural referral centers, sole community hospitals, and freestanding cancer centers. Additionally in 2010, HRSA allowed for 340B entities to sign agreements with more than one outside pharmacy ...

The federal government is rolling back a pandemic-era waiver that lowered the bar for 340B ... of Policy and Advocacy Beth Feldpush said her group was disappointed with the reversal. HRSA ...

In the face of HRSA inaction, some manufacturers, including Sanofi Aventis and Novartis, have adopted policies for their 340B dealings with covered entities meant to limit diversion and double ...

Although the Proposal largely reaffirms many of HRSA's existing policy interpretations, it also contains some significant changes, including proposals that are likely to limit 340B patient ...

A group of health systems from across the country is seeking to block the Health Resources and Services Administration from reinstating a registration policy for offsite clinics of 340B-eligible ...

The court filing reverses the HRSA ... 340B drug discounts for contract pharmacies continues, however. HRSA could still try to force the companies into compliance even without a blanket policy.

On Tuesday, the Health Resources and Services Administration (HRSA ... arguing the policy shift violated statute. Currently, drugmakers are required to provide the 340B price at the time of ...